Patient and public involvement: well-being is key Clinical research has too often assumed what is best for patients and failed to capture the lived experience of those living with type 2 diabetes: lower HbA 1c will not necessarily improve patient-reported outcomes
In the same spirit, some players focus on hospitality touchesthings like personalized suggestions, practical tutorials, and friendly onboarding
Warning: Do not exceed recommended dose
The focus on preventive care and chronic disease management is another factor that helps North America to be at the forefront of the GLP-1 analogues industry
Table 1 GLP-1 analogues available in the market Exenatide Exenatide, sold under the brand name Byetta, was jointly developed by Amylin and Lily in the United States
With those caveats stated clearly, here is what practitioners who are using this approach are documenting